PERSEUS SENOLYTIX
LIVE

Serial Number

99351616

Owner

SENOTHERAPEUTIX, Inc.

Attorney

Jared L. DuJack

Filing Date

Aug 22, 2025

Add to watchlist:

No watchlists yet
View on USPTO

PERSEUS SENOLYTIX Trademark

Serial Number: 99351616

PERSEUS SENOLYTIX is a trademark filed by SENOTHERAPEUTIX, Inc. on August 22, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

SENOTHERAPEUTIX, Inc. (2 trademarks)

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

August 22, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Synthesized peptides for use in cancer and age-related diseases; Synthesized peptides for use in skin conditions; Synthesized anti-cancer peptides; Synthesized anti-aging peptides; Synthesized peptides for use in prevention of radiation damage; Synthesized peptides for use in treatment of radiation damage; Synthesized peptides for use in prevention of radiation related diseases; Synthesized peptides for use in treatment of radiation related diseases

Medical research services; Medical research services, namely, anti-cancer and anti-aging medical research services; Medical research services in the field of prevention and treatment of cancer and age-related disorders; Medical research laboratory services; Medical research laboratory services related to cancer; Medical research laboratory services related to biologic age; Medical research laboratory services related to biological age scoring; Medical research laboratory services related to determining a number or percentage of senescent cells; Non-invasive pathological testing for medical research purposes; Non-invasive pathological testing related to cancer for medical research purposes; Non-invasive pathological testing related to biologic age for medical research purposes; Non-invasive pathological testing related to biological age scoring for medical research purposes; Non-invasive pathological testing related to determining a number or percentage of senescent cells for medical research purposes; Medical research on the prevention of cancer; Medical research on the treatment of cancer; Medical research on the prevention of radiation damage; Medical research on the treatment of radiation damage; Medical research on the prevention of radiation related diseases; Medical research on the treatment of radiation related diseases; Medical research in the field of anti-cancer; Medical research in the field of anti-aging; Development of pharmaceutical preparations and medicines; Research and development of pharmaceuticals for the treatment of cancer and age-related diseases; Testing, inspection, research, and development of pharmaceutical preparations for cancer therapy and age therapy; Consulting services in the fields of biotechnology, and pharmaceutical research and development

Medical services in the field of anti-cancer therapy; Medical services in the field of anti-cancer services; Medical services in the field of anti-aging therapy; Medical services in the field of anti-aging medical services; Consulting services in the fields of medical testing and medical diagnostic services; Medical testing services, namely, biologic age scoring; Medical testing services, namely, statistical scoring to determine a biologic age score of a patient; Medical services; Medical services, namely, anti-cancer and anti-aging services; Medical services, namely, prevention and treatment of cancer and age-related disorders; Medical advisory services; Medical advisory services in the field of anti-cancer and anti-aging services; Medical advisory services in the field of prevention and treatment of cancer and age-related disorders; Medical testing services; Medical testing services, namely, medical testing for anti-cancer and anti-aging; Medical testing services, namely, medical testing for the prevention and treatment of cancer and age-related disorders; Medical services in the field of anti-cancer and anti-aging; Medical services in the field of senescent cells; Medical services in the field of cancer and age-related disorders; Biopsy services in the nature of medical testing services; Biopsy services in the nature of medical testing services related to cancer; Biopsy services in the nature of medical testing services related to biologic age; Biopsy services in the nature of medical testing services related to biological age scoring; Biopsy services in the nature of medical testing services related to determining a number or percentage of senescent cells; Medical treatment of cancer; Medical treatment of radiation damage; Medical treatment of radiation related diseases

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 22, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 22, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 22, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 20, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 20, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 22, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 13, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 12, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 22, 2025 MAFR
NEW APPLICATION ENTERED
Aug 22, 2025 NWAP